Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/27/2024 | $5.00 | Outperform | BMO Capital Markets |
| 4/9/2024 | $9.00 | Overweight | Piper Sandler |
| 2/1/2023 | $14.00 → $1.50 | Buy → Hold | Jefferies |
| 1/27/2023 | $23.00 → $3.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/9/2022 | $16.00 → $3.00 | Buy → Neutral | Goldman |
| 3/9/2022 | $26.00 | Outperform | Robert W. Baird |
| 3/9/2022 | $26.00 | Outperform | Baird |
| 3/1/2022 | $25.00 | Overweight | Wells Fargo |
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Ta
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration achieved comparable biodistribution across brain and spinal cord regions in NHPs Findings from the analysis reaffirm the clinical potential of IT administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in both children and adults DALLAS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on adv
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.
10-Q - Taysha Gene Therapies, Inc. (0001806310) (Filer)
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)
SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)
BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00
Piper Sandler initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $9.00
Jefferies downgraded Taysha Gene Therapies from Buy to Hold and set a new price target of $1.50 from $14.00 previously
Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients TSHA-102 was generally well tolerated with no SAEs or DLTs as of initial six-week assessment in first patient in cohort two (high dose) of adolescent/adult trial; IDMC approved dosing of second (adolescent/adult trial) and first (pediatric trial) patient in cohort two, which is scheduled for Q3 2024 Cohort two (n=3) and cohort one (n=2) data from both trials (adolescent/adult and pediatric) expected in 1H 2
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2024, and host a corporate update conference call and webcast on Monday, August 12, 2024, at 8:30 AM Eastern Time. Conference Call DetailsMonday, August 12, 2024, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free:877-407-0792International:201-689-8263Conference ID:13747741Webcast:https://ir.tayshagtx.com/news-events/events-presenta
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lowe
14 analysts have expressed a variety of opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 7 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 3 3 0 0 0 3M Ago 3 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.79, a high estimate of $8.00, and a low estimate of $5.00. Witnessing a positive shift, the c
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
Piper Sandler analyst Christopher Raymond maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and lowers the price target from $9 to $7.